Hanmi Pharm. Co., Ltd.

Jong Ouk Baek

Tae Hee Ha

Jae Hyuk Jung

Hee Seok Kim

Kwee Hyun Suh

Ho Seok Kim

Eun Joo Kwak

Hee Sook Oh

Ji Young Jeon

Sun Young Jang

Sun Young Jung

A crystalline form of an alkyl benzene sulfonyl urea compound that is useful as an oral antidiabetics is disclosed. Specifically, the compound is a hydrochloride salt of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide of the following formula I. A pharmaceutical composition containing the compound is also disclosed: 

Crystalline forms of hydrochloride salts of thienopyrimidine compound

The present invention relates to crystalline forms of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, and pharmaceutical compositions containing the same. The crystalline forms can be easily used for the preparation of a pharmaceutical composition containing the same as an active ingredient.

Crystalline forms of thienopyrimidine compound

A method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase. Intermediates used in the method are provided.

Method for preparing thienopyrimidine compound and intermediates used therein

The present invention provides a novel method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase, and novel intermediates used in the method.

Growing community of inventors

Seoul, South Korea

Jong Ouk Baek